Unicycive Therapeutics Files 8-K Report
Ticker: UNCY · Form: 8-K · Filed: Aug 15, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $4.56, $16.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, company-info
TL;DR
Unicycive Therapeutics filed an 8-K on 8/15/25, confirming their address and reporting status.
AI Summary
On August 15, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022. The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This filing provides official notification of the company's reporting status and key contact information to the SEC and the public.
Risk Assessment
Risk Level: low — This is a routine filing that primarily confirms company information and reporting status, not indicating any new material events or risks.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
- 4300 El Camino Real, Suite 210, Los Altos, CA 94022 (address) — Principal executive offices
- Securities Exchange Act of 1934 (legal_document) — Reporting Act
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Unicycive Therapeutics, Inc.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 15, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Commission File Number for Unicycive Therapeutics, Inc.?
The Commission File Number for Unicycive Therapeutics, Inc. is 001-40582.
Filing Stats: 401 words · 2 min read · ~1 pages · Grade level 13.1 · Accepted 2025-08-15 16:30:34
Key Financial Figures
- $4.56 — of common stock at an average price of $4.56 per share, resulting in net proceeds to
- $16.3 million — roceeds to the Company of approximately $16.3 million. 1 SIGNATURE Pursuant to the requi
Filing Documents
- ea0253521-8k_unicycive.htm (8-K) — 28KB
- 0001213900-25-077497.txt ( ) — 191KB
- uncy-20250815.xsd (EX-101.SCH) — 3KB
- uncy-20250815_lab.xml (EX-101.LAB) — 33KB
- uncy-20250815_pre.xml (EX-101.PRE) — 22KB
- ea0253521-8k_unicycive_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 Unicycive Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40582 81-3638692 (State or other jurisdiction (Commission File Number) ( IRS Employer of incorporation or organization) Identification No.) 4300 El Camino Real , Suite 210 Los Alto , CA 94022 (Address of principal executive offices) Registrant's telephone number, including area code: ( 650 ) 351-4495 (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock UNCY Nasdaq Capital Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. Subsequent to June 30, 2025, pursuant to a sales agreement dated November 13, 2024 with Guggenheim Securities, LLC, Unicycive Therapeutics, Inc. (the " Company") sold 3,549,846 shares of common stock at an average price of $4.56 per share, resulting in net proceeds to the Company of approximately $16.3 million. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 15, 2025 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer 2